Literature DB >> 11384686

A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1.

P N Nyambi1, S Burda, L Bastiani, C Williams.   

Abstract

This protocol describes a simple assay that can be used to study the nature of exposure of antigenic epitopes and antigenic relatedness of different intact, native HIV-1 strains. The assay is based on the principle that mAbs coated on microtiter wells bind to epitopes on the surface of intact, native virions. The bound virion is then lysed to release p24, which is then quantitated (pg/ml) to give a measure of the amount of virion bound to the mAb. High p24 levels released after lysis correlate with high level capture of virions by mAbs, and as such, reflect good exposure of the epitope on the virion. Likewise, binding patterns of a specific mAb with different virus strains reveal information on their antigenic relatedness. In establishing this assay, the nature of exposure of antigenic epitopes and the antigenic relatedness of six intact, native HIV-1 virions of clades A, B, C, D, F and G were examined using anti-HIV-1 mAbs directed at epitopes in the V2, V3, CD4bd and C5 of gp120, and in clusters I and II of the gp41 region. Analysis of the binding data shows that mAbs directed at epitopes in the V3, C5 and gp41 Cluster I region bound best to the viruses examined, suggesting that these are the regions most exposed and conserved on intact, native HIV-1 virions of different clades. Epitopes in the V2 and CD4bd of gp120, and in gp41 cluster II, are not exposed on intact, native virions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384686     DOI: 10.1016/s0022-1759(01)00384-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Nanoparticle-based flow virometry for the analysis of individual virions.

Authors:  Anush Arakelyan; Wendy Fitzgerald; Leonid Margolis; Jean-Charles Grivel
Journal:  J Clin Invest       Date:  2013-08-08       Impact factor: 14.808

2.  Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope.

Authors:  Yossef Raviv; Mathias Viard; Julian W Bess; Elena Chertova; Robert Blumenthal
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Characterization of the effects of aryl-azido compounds and UVA irradiation on the viral proteins and infectivity of human immunodeficiency virus type 1.

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; Michael Jason de la Cruz; Kunio Nagashima; Robert Blumenthal
Journal:  Photochem Photobiol       Date:  2010 Sep-Oct       Impact factor: 3.421

4.  Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Authors:  C Moog; N Dereuddre-Bosquet; J-L Teillaud; M E Biedma; V Holl; G Van Ham; L Heyndrickx; A Van Dorsselaer; D Katinger; B Vcelar; S Zolla-Pazner; I Mangeot; C Kelly; R J Shattock; R Le Grand
Journal:  Mucosal Immunol       Date:  2013-04-17       Impact factor: 7.313

5.  Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.

Authors:  Phillipe Nyambi; Sherri Burda; Mateusz Urbanski; Leo Heyndrickx; Wouter Janssens; Guido Vanham; Arthur Nadas
Journal:  AIDS Res Hum Retroviruses       Date:  2008-12       Impact factor: 2.205

6.  Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.

Authors:  Raiees Andrabi; Rajesh Kumar; Manju Bala; Ambili Nair; Ashutosh Biswas; Naveet Wig; Pratik Kumar; Rahul Pal; Subrata Sinha; Kalpana Luthra
Journal:  Virol J       Date:  2012-09-12       Impact factor: 4.099

7.  Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.

Authors:  Bijayesh Haldar; Sherri Burda; Constance Williams; Leo Heyndrickx; Guido Vanham; Miroslaw K Gorny; Phillipe Nyambi
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

8.  The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity.

Authors:  Céline Amadori; Yme Ubeles van der Velden; Damien Bonnard; Igor Orlov; Nikki van Bel; Erwann Le Rouzic; Laia Miralles; Julie Brias; Francis Chevreuil; Daniele Spehner; Sophie Chasset; Benoit Ledoussal; Luzia Mayr; François Moreau; Felipe García; José Gatell; Alessia Zamborlini; Stéphane Emiliani; Marc Ruff; Bruno P Klaholz; Christiane Moog; Ben Berkhout; Montserrat Plana; Richard Benarous
Journal:  Retrovirology       Date:  2017-11-09       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.